Nyrada Inc (ASX:NYR) has received additional study data to support the safety and tolerability of its lead brain injury drug candidate
A specialist in novel small molecule therapeutics, Nyrada is developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke. In February 2024, the company reported preclinical stroke study results showing NYR-BI03 provided a statistically significant level of neuroprotection, rescuing 42% of brain injury in the penumbra region in treated animals.
In late 3QFY 2024, Good Laboratory Practice (GLP) studies commenced to assess safety and tolerability of NYR-BI03. In July 2024, Nyrada reported the results of hERG and AMES testing.
Nyrada has now reported that NYR-BI03 demonstrated safety and tolerability in a modified Irwin Rat CNS (central nervous system) test.
The Irwin CNS test is a method used to evaluate how a drug impacts the central nervous system. Researchers observe and record any changes in behaviour, movements, or activity levels. This helps determine if the drug causes any side effects related to the brain and nervous system, ensuring the drug's safety for further development.
This test evaluated the effects of NYR-BI03 on the central nervous system by assessing neurological functions with escalating doses of NYR-BI03.
